The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

More than 1.6 million Britons are set to get the 'King Kong' of fat jabs on the NHS over the next 12 years.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Ozempic and other diabetes-weight loss drugs have been linked to at least 162 deaths and 10,000 cases involving “serious” ...

“Its patent will expire next year, and it will be available as a generic and I will introduce it to the entire public health ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...

Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...

God knows what volume they’re actually selling. And who knows? You’re just taking it,” one expert told The Post.

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

The drug, called Mounjaro in the UK and Zepbound in the U.S., would be initially offered to obese people with at least three ...